Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041515 | 1.00 | NOS1 (0.49) | NOS1SMN1; SMN2PARP1PARP2BRD4 | |
| SCHEMBL17117210 | 0.84 | SMN1; SMN2 (0.41) | NOS1SMN1; SMN2BRD4ALDH1A1MAPT | |
| SCHEMBL14251056 | 0.83 | NOS1 (0.49) | NOS1SMN1; SMN2PARP1PARP2BRD4 | |
| SCHEMBL29410544 | 0.82 | MAPT (0.40) | NOS1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL12696878 | 0.82 | DDB1 (0.40) | NOS1SMN1; SMN2PARP1PARP2ALDH1A1 | |
| SCHEMBL10242198 | 0.81 | CHRNB2 (0.53) | SMN1; SMN2ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL19587006 | 0.80 | ALDH1A1 (0.40) | SMN1; SMN2PARP1PARP2BRD4ALDH1A1 | |
| SCHEMBL27898379 | 0.80 | CYP19A1 (0.41) | NOS1PARP1PARP2MAPTKMT2A | |
| SCHEMBL31324258 | 0.80 | ESR2 (0.44) | NOS1PARP1PARP2ALDH1A1KDM4E | |
| SCHEMBL27761702 | 0.80 | NOTUM (0.37) | NOS1PARP1PARP2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025003925-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2025-01-02 | — | — | WO | claimed |
| EP-4484422-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | Tallinn University of Technology (EE) | 2025-01-01 | — | — | EP | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| US-20260125394-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2026-05-07 | — | — | US | disclosed |
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025003925-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2025-01-02 | — | — | WO | disclosed |
| EP-4484422-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | Tallinn University of Technology (EE) | 2025-01-01 | — | — | EP | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-1497267-B1 | METHOD FOR THE PRODUCTION OF CHIRAL IMIDAZOLIDIN-2-ONES | BASF SE (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-7365210-B2 | Method for the production of chiral imidazolidin-2-ones | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-29 | — | — | US | disclosed |
| EP-1781620-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005108373-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| US-20050165078-A1 | evolution of ammonia is virtually completely avoided; reduction in sublimation of urea, as occurs on reaction in the melt; high purity of the crude product means that further recrystallization is usually unnecessary | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1497267-A2 | METHOD FOR THE PRODUCTION OF CHIRAL IMIDAZOLIDIN-2-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003084933-A2 | METHOD FOR THE PRODUCTION OF CHIRAL IMIDAZOLIDIN-2-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | NOS1 4315/4885SMN1; SMN2 9/4885PARP1 43/4885 |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | NOS1 507/4885SMN1; SMN2 1888/4885PARP1 4452/4885 |
| US-20260125394-A1 | METHOD OF PREPARATION OF CHIMERIC HEMICUCURBIT[N]URILS, DERIVATIVES, AND USES THEREOF | HTT, PRNP, URB2 | NOS1 3365/4885SMN1; SMN2 2542/4885PARP1 563/4885 |
| US-20050165078-A1 | evolution of ammonia is virtually completely avoided; reduction in sublimation of urea, as occurs on reaction in the melt; high purity of the crude product means that further recrystallization is usually unnecessary | CBR3, NPM1, C1S | NOS1 181/4885SMN1; SMN2 2302/4885PARP1 3915/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | NOS1 507/4885SMN1; SMN2 1888/4885PARP1 4452/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | NOS1 4224/4885SMN1; SMN2 22/4885PARP1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.